Merck & Company (MRK) Stock Price, Quote & News

Company Profile

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The company offers human health pharmaceutical for various areas, including oncology, vaccines, hospital acute care, cardiovascular, virology, neuroscience, and diabetes under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 908 740 4000

Website: www.merck.com

Address:

126 East Lincoln Avenue, Rahway, United States

ZacksResearch Aug. 12 at 5:00 AM

$MRK tightens 2025 sales outlook — but EPS guidance edges higher 📈 Keytruda, Animal Health, and new drug launches are all expected to fuel a stronger second half despite the narrowed sales range. Full breakdown of the post-Q2 setup here 👉 https://www.zacks.com/stock/news/2697807/mercks-narrowed-2025-sales-view-what-it-means-after-q2-results?cid=sm-stocktwits-2-2697807-teaser-7183&ADID=SYND_STOCKTWITS_TWEET_2_2697807_TEASER_7183

0 · Reply

MaisieFlynn Aug. 12 at 4:53 AM

$MRK Follow the price target.

0 · Reply

Baerchen Aug. 12 at 1:29 AM

$FHTX When watching their latest presentation, focus was mostly on combination with in-house Olomorasib from LLY itself - LLY bought Loxo Oncology 2019 at 235$ - IPO was 13$ - Loxo was oncology specialty - since LLY has still interest in oncology and $FHTX is leading in this field - just the future knows. Big Pharma has to specialize in the future. LLY tends to go for Oncology/Diabetes/Obesity. $MRK tends to go for Immunology. $GILD goes for Infectious disease and somehow Liver disease. Vaccines are not that interesting anymore. KRAS has been an interesting topic. But $FHTX also seems to be more focusing in combining therapeutics, so they can partner up with any chinese Biotech or some PD1(L) - and get any results. Hot shit I think. Great management.

0 · Reply

TheTinMan Aug. 12 at 1:07 AM

$TLTFF this could pop in the coming days or weeks. NMIBC Phase 2 study numbers soon and potential HSV cure/treatment in the early but extremely promising stage $JNJ $MRK $AZN $IBRX

1 · Reply

sister Aug. 11 at 8:22 PM

$MRNA bullish news here for return to 34.88 -- was $170.47 not so long ago 10:55:35 FDA May Not Renew Pfizer's Authorization For Covid Shots In Younger Children, Moderna Prepares To Boost Supply $MRK $PFE

0 · Reply

wjmax Aug. 11 at 5:39 PM

$MRK The CEO said the following in April. Can somone point out what are the 20 new growth drivers that have blockbuster potential? "Together, our efforts have resulted in an expanded late-phase pipeline, comprising programs having potential commercial opportunity of over $50 billion by the mid-2030s. WINREVAIR and CAPVAXIVE represent the initial launches from this robust pipeline of 20 promising potential new growth drivers we expect to come to the market over the next few years, almost all of which have blockbuster potential."

0 · Reply

Quantumup Aug. 11 at 5:30 PM

H.C. Wainwright⬇️ $URGN's PT to $40 from $50, reiterated at a Buy and said, "we still believe that UroGen could reach cash flow-positive status in 2H26," after late last week the Co. reported its 2Q25 financial results. $JNJ $MRK H.C. Wainwright additionally said: The company recorded 2Q25 top-line revenue totaling $24.2M, missing our forecast of $25.9M. We note, however, that investors are likely looking past the historical track record with the firm's first marketed product, JELMYTO (mitomycin C pyelocalceal solution for treatment of upper tract urothelial carcinoma, or UTUC), and ahead to the commercial rollout of ZUSDURI (formerly UGN-102, mitomycin C intravesical solution) in low-grade, intermediate-risk non-muscle-invasive bladder cancer (LG-IR-NMIBC). Year-over-year revenue growth of 11% for JELMYTO was driven by underlying demand growth of 7% and price favorability. H.C. Wainwright went on to say:

0 · Reply

ZacksResearch Aug. 11 at 4:18 PM

0 · Reply

sister Aug. 11 at 3:37 PM

$MRNA added large @ 25.75 for Fast Snapback to 34.88 initially . . . was $170.47 not so long ago. $MRK $GILD

0 · Reply

ZacksResearch Aug. 11 at 3:18 PM

$MRK is down 18.8% YTD — is it a value play now? 🤔 Despite mixed earnings and sales results, Merck's blockbuster Keytruda surged 9% year over year, and Animal Health saw an 11% boost. Plus, MRK's forward P/E is a bargain at 8.64 compared to the industry average of 13.71. Opportunity assessment here 👉 https://www.zacks.com/stock/news/2697807/mercks-narrowed-2025-sales-view-what-it-means-after-q2-results?cid=sm-stocktwits-2-2697807-body-7179&ADID=SYND_STOCKTWITS_TWEET_2_2697807_BODY_7179

0 · Reply

August Dogs Of The Dow Unleashed 19 'Safer' Dividend Buys

AMGN AMZN BA CRM CVX DIS HD

Aug 6, 2025, 10:30 AM EDT - 5 days ago

Stock Picks From Seeking Alpha's July 2025 New Analysts

ACCO ACSI AIZ AJG ALHC AMD CPRI

Aug 5, 2025, 10:03 AM EDT - 6 days ago

Income Strategy: I'm Buying 2 Elite Mispriced Dividends

REXR

Aug 2, 2025, 8:01 AM EDT - 9 days ago

5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8.5% (August 2025)

ADP AMH APH ARCC ASR AVGO BTI

Aug 1, 2025, 12:01 PM EDT - 10 days ago

Pharmaceutical makers were largely unshaken by new demands from President Trump to lower drug prices, with experts saying the measures would either have modes impact or face legal challenges

ABBV AMGN AZN BMY GILD GSK JNJ

Aug 1, 2025, 8:31 AM EDT - 10 days ago

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

ABBV ABT ALNY AMGN ARGX AZN BAX

Aug 1, 2025, 7:15 AM EDT - 10 days ago

Top 10 High-Yield Dividend Stocks For August 2025

CMCSA NEE

Aug 1, 2025, 6:54 AM EDT - 10 days ago

President Trump demands drugmakers slash prices within 60 days

ABBV ABT ALNY AMGN ARGX AZN BAX

Aug 1, 2025, 4:31 AM EDT - 10 days ago

European drugmakers fall after Trump raises stakes over US drug price cuts

AZN NVO SNY

Jul 31, 2025, 3:35 PM EDT - 11 days ago

Pharma Companies Should Immediately Cut Down Drug Prices, Trump Says

ABBV AMGN AZN BMY GILD GSK JNJ

Jul 31, 2025, 3:00 PM EDT - 11 days ago

Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days.

ABBV AMGN AZN BMY GILD GSK JNJ

Jul 31, 2025, 2:28 PM EDT - 11 days ago

Trump pressures 17 pharma CEOs to cut US drug prices

ABBV AMGN AZN BMY GILD GSK JNJ

Jul 31, 2025, 2:19 PM EDT - 11 days ago

Trump posts letters to 17 pharmaceutical companies about drug prices

ABBV GILD LLY PFE AMGN AZN BMY

Jul 31, 2025, 1:48 PM EDT - 11 days ago

Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days

ABBV AMGN AZN BMY GILD GSK JNJ

Jul 29, 2025, 3:03 PM EDT - 13 days ago

Merck Stock Is Almost A Classical Benjamin Graham Investment

Jul 29, 2025, 1:47 PM EDT - 13 days ago

Merck & Co., Inc. (MRK) Q2 2025 Earnings Call Transcript

Jul 29, 2025, 1:45 PM EDT - 13 days ago

'Halftime' Committee Stocks on the Move: UnitedHealth, Merck, Royal Caribbean and Spotify

RCL SPOT UNH

Jul 29, 2025, 10:08 AM EDT - 13 days ago

Merck will lay off employees and shed some real estate to cut $3 billion in costs

Jul 29, 2025, 7:03 AM EDT - 13 days ago

Merck plans $3 billion cost cuts by end of 2027 - narrows full-year outlook

Jul 29, 2025, 6:40 AM EDT - 13 days ago

Merck to Lay Off Workers and Narrows Guidance as Earnings Fall

Jul 29, 2025, 6:36 AM EDT - 13 days ago

Merck to cut jobs and costs as demand for Gardasil in China remains weak

Jul 29, 2025, 6:31 AM EDT - 13 days ago

Merck plans $3 billion cost cuts by end of 2027 narrows full-year outlook

Jul 29, 2025, 6:30 AM EDT - 13 days ago

Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2025 Financial Results

Jul 28, 2025, 2:06 PM EDT - 14 days ago

Evercore ISI's Umer Raffat on finding value in the beaten-down health care sector

ABBV BMY CI CVS HUM XBI XLV

Jul 28, 2025, 8:12 AM EDT - 14 days ago

How To Earn $500 A Month From Merck Stock Ahead Of Q2 Earnings

Jul 28, 2025, 7:25 AM EDT - 14 days ago

Sell Merck Stock Ahead Of Its Upcoming Earnings?

Jul 25, 2025, 5:25 AM EDT - 17 days ago

U.S. Keytruda Market Research Report 2025 | Merck's Keytruda Faces Challenges as Patent Expiry Approaches in 2028 - Forecast to 2033

Jul 23, 2025, 9:57 AM EDT - 19 days ago

Five years after COVID, pharma shares languish in US policy limbo

ABBV ABT ALNY AZN EW LLY NVO

Jul 22, 2025, 4:07 PM EDT - 20 days ago

Dow Leads as Health Care Stocks Merck and Amgen Gain: Stock Market Today

AMGN

Jul 22, 2025, 11:53 AM EDT - 20 days ago

Merck Announces Fourth-Quarter 2025 Dividend

Jul 22, 2025, 9:18 AM EDT - 20 days ago

Rapid Micro Biosystems: Benefiting From Partnership With Merck; Initiating With 'Buy'

RPID

Jul 21, 2025, 10:00 AM EDT - 21 days ago

Merck Commits to Veeva Vault CRM

VEEV

Jul 18, 2025, 2:46 PM EDT - 24 days ago

July's 5 Dividend Growth Stocks With Yields Up To 7.96%

ABBV APAM BLK BMY EBF NWE PFE

Jul 18, 2025, 5:06 AM EDT - 24 days ago

Livestock Identification Company Evaluation Report 2025 | Merck, Shearwell, Datamars Drive Innovations with Comprehensive Tagging and Tracking Solutions

Jul 17, 2025, 6:24 PM EDT - 25 days ago

Merck & Co., Inc. (MRK) Presents at HIV Investor Event Transcript

Jul 16, 2025, 3:08 PM EDT - 26 days ago

Why Merck Is A Better Dividend Stock Than Gilead Sciences

GILD

Jul 16, 2025, 7:00 AM EDT - 26 days ago

Amphista Therapeutics announces achievement of a research milestone in its collaboration with Merck triggering a milestone payment

Jul 14, 2025, 9:31 AM EDT - 4 weeks ago

Merck to Initiate Phase 3 Trials for Investigational Once-Monthly HIV Prevention Pill

Jul 12, 2025, 9:09 PM EDT - 4 weeks ago

VERONA PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verona Pharma plc - VRNA

VRNA

Jul 11, 2025, 7:10 AM EDT - 4 weeks ago

Merck's Verona Acquisition: Plugging A $4B Hole In A $20B Gap

Jul 10, 2025, 4:45 PM EDT - 4 weeks ago

FDA Approves BRAVECTO® QUANTUM (Fluralaner for Extended-Release Injectable Suspension) from Merck Animal Health

Jul 10, 2025, 6:45 AM EDT - 4 weeks ago

U.S. FDA Accepts New Drug Application for Merck's Doravirine/Islatravir, an Investigational, Once-Daily, Oral, Two-Drug Regimen for Treatment of Adults with Virologically Suppressed HIV-1 Infection

Jul 9, 2025, 4:00 PM EDT - 4 weeks ago

Measuring Options Activity in MRK & XLV: Healthcare Levels to Watch

XLV

Jul 9, 2025, 1:46 PM EDT - 4 weeks ago

Major deals involving U.S. drugmakers and biotechs over the past decade

VRNA

Jul 9, 2025, 12:59 PM EDT - 4 weeks ago

Undercovered Dozen: Roku, Merck, Chevron And More

CVX ROKU

Jul 9, 2025, 12:36 PM EDT - 4 weeks ago

Merck to Buy Verona Pharma for Around $10 Billion

VRNA

Jul 9, 2025, 10:36 AM EDT - 4 weeks ago

Merck has struck a roughly $10 billion deal to buy Verona Pharma

VRNA

Jul 9, 2025, 10:30 AM EDT - 4 weeks ago

META Stake in Ray-Ban & Oakley Maker, MRK Acquiring VRNA, TMUS Downgrade

META TMUS

Jul 9, 2025, 9:23 AM EDT - 4 weeks ago

Merck to buy Verona for $10 billion ahead of Keytruda patent expiration

ZacksResearch Aug. 12 at 5:00 AM

0 · Reply

MaisieFlynn Aug. 12 at 4:53 AM

$MRK Follow the price target.

0 · Reply

Baerchen Aug. 12 at 1:29 AM

0 · Reply

TheTinMan Aug. 12 at 1:07 AM

$TLTFF this could pop in the coming days or weeks. NMIBC Phase 2 study numbers soon and potential HSV cure/treatment in the early but extremely promising stage $JNJ $MRK $AZN $IBRX

1 · Reply

sister Aug. 11 at 8:22 PM

0 · Reply

wjmax Aug. 11 at 5:39 PM

0 · Reply

Quantumup Aug. 11 at 5:30 PM

0 · Reply

ZacksResearch Aug. 11 at 4:18 PM

0 · Reply

sister Aug. 11 at 3:37 PM

$MRNA added large @ 25.75 for Fast Snapback to 34.88 initially . . . was $170.47 not so long ago. $MRK $GILD

0 · Reply

ZacksResearch Aug. 11 at 3:18 PM

0 · Reply

StocktwitsNews Aug. 11 at 2:58 PM

IO Biotech Stock Slumps After Trial Of Cancer Therapy Plus Keytruda Misses Study Goal: Retail Sees Shares Rise 10x $IOBT $MRK https://stocktwits.com/news/equity/markets/io-biotech-trial-of-cancer-therapy-plus-keytruda-misses-study-goal/chrHGKVRdeB

0 · Reply

biolover Aug. 11 at 2:27 PM

$PFE will do better than $MRK Way undervalued compared to Merck Pfizer management is looking strategic and long term , MRK leadership now looking how to generate some revenues in 2028 to cover kytruda LOE .. they continue to execute short sighted deals. MRK lack of emphasis on obesity is a red flag ( compared to Pfizer , Abbv , Roche and other BP) and reflect poor leadership. Lilly tirzepatide in 2 years achieved what took kytruda 12 years and TP still not in half cycle If Pfizer pulls a deal with $VKTX , expect it to easily surpass Merck MC by year end.

1 · Reply

sister Aug. 11 at 1:31 PM

$MRNA Squeeze coming with mrNA Vaccines Expert calling out RFK Jr saying "He doesn't know what he's talking about" $PFE $MRK

1 · Reply

ZacksResearch Aug. 11 at 1:26 PM

$MRK down after Q2 — buy the dip or bail? Gardasil sales dragged the quarter, but Keytruda strength, new launches, and a deep pipeline keep the long-term story alive. Full game plan here 👉 https://www.zacks.com/stock/news/2697107/merck-stock-down-4-since-q2-results-how-to-play-the-stock?cid=sm-stocktwits-2-2697107-teaser-7066&ADID=SYND_STOCKTWITS_TWEET_2_2697107_TEASER_7066

0 · Reply

Jeasie Aug. 11 at 12:56 PM

$MRK This should be over $100.00

0 · Reply

ZacksResearch Aug. 11 at 12:26 PM

$MRK dips 4% post-earnings — time for concern or opportunity? 🤔 📉 EPS declined 7% year over year, revenue down 2% 💊 Keytruda sales up 9% — remains a key driver 🔍 New products Capvaxive & Winrevair show promise 💡 Long-term fundamentals strong despite near-term challenges Should long-term investors stay the course? Full analysis here 👉 https://www.zacks.com/stock/news/2697107/merck-stock-down-4-since-q2-results-how-to-play-the-stock?cid=sm-stocktwits-2-2697107-body-7058&ADID=SYND_STOCKTWITS_TWEET_2_2697107_BODY_7058

0 · Reply

Tom2772 Aug. 11 at 6:38 AM

$NVO $LLY $MRK

1 · Reply

Tom2772 Aug. 11 at 6:37 AM

$NVO $LLY $MRK Don't forget that there is much more to report on Novo Nordisk's pipeline in anticipation of 2025 FDA, Health Canada reviewing semaglutide for liver disease MASH Formulation, dosage already approved to help with weight loss. Both health authorities gave the applications priority review, meaning decisions should be available in about six months, instead of the standard 10 months. https://liverdiseasenews.com/news/semaglutide-under-review-us-canada-treatment-fatty-liver-disease-mash/

1 · Reply

sister Aug. 11 at 3:47 AM

$MRNA Squeezes higher w/ Dr Paul Offit defending MRNA vaccine development saying "He [RFK Jr.] doesn't know what he's talking about . . . " But we already knew that lol. $UNH $MRK

0 · Reply

JonCollins Aug. 11 at 3:38 AM

Big pharma like $PFE and the like could benefit bigly as the yanks say with marijuana cannabis rescheduling & SAFE banking. "A rising tide lifts all ships." https://www.tipranks.com/news/trump-considers-cannabis-reclassification-that-could-boost-45-billion-u-s-market $JNJ $MRK $BMY

0 · Reply

BiotechBonesaw Aug. 10 at 8:58 PM

$TNXP $IMRX $SLS $PPBT $MRK Every day is a good day! All of these stocks help patients that struggle from major conditions. Biotech is an incredible sector to invest in if you ignore the bullshit. Every Day is a gift. Treat it as such. 🎁

0 · Reply

Gps_100X_ROI_Potential Aug. 9 at 9:13 PM

$SLS Trial was Enrolling during the Teeth of the COVID Pandemic. A. and B. The FINAL RESULTS are phenomenal. The Dr's Co-Authoring the Paper, which includes Merck Dr. Julie Cohen, Concluded a Phase 3 trial is warranted. Which in MED SPEAK is extremely bullish. - furthermore, the dr's explain that Gps + Key/any CPI will work Even Better in Earlier Patient Settings, prior to the advanced End stage like this trial, where GPS + key MOS of 18.4 months is Better than Elahere $IMGN that was bought for 10.1B based on an MOS of just 16.46 Months in the same Setting. Similarly, $CORT just published p3 data, its drug relacoriant? + Intensive Chemo achieved an MOS of 16.5 months in this PROC setting - its Market Value Jumped $4B the day of the announcement. and GPS + Key $MRK is Better.

2 · Reply

Market Cap	201.55B
Revenue (ttm)	64.17B
Net Income (ttm)	17.12B
EPS (ttm)	N/A
PE Ratio	10.52
Forward PE	8.99
Profit Margin	26.68%
Debt to Equity Ratio	0.69

Volume	8,210,700
Avg Vol	14,952,340
Day's Range	N/A - N/A
Shares Out	2.50B
Stochastic %K	41%
Beta	0.38
Analysts	Strong Sell
Price Target	$102.05